Verastem, Inc.
VSTMVerastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
Drugs in Pipeline
16
Phase 3 Programs
1
Upcoming Catalysts
6
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
6 upcoming, 1 past
How VSTM's past catalysts played out
avutometinib
Low Grade Serous Ovarian Cancer
avutometinib (VS-6766)
Low Grade Ovarian Serous Adenocarcinoma
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
KRAS Activating Mutation
Avutometinib (VS-6766) + Defactinib (VS-6063)
Low Grade Serous Ovarian Cancer
defactinib (VS-6063)
Non Small Cell Lung Cancer
avutometinib (VS-6766) and adagrasib
Non Small Cell Lung Cancer
avutometinib and sotorasib
Non Small Cell Lung Cancer
avutometinib (VS-6766) and Defactinib
Non Small Cell Lung Cancer
panitumumab
Colorectal Cancer
Duvelisib
COVID-19
VS-6766
Breast Cancer
Avutometinib (VS-6766) + defactinib
Endometrioid Cancer
Defactinib
Pancreatic Adenocarcinoma
Encorafenib
Cutaneous Melanoma
VS-7375
Pancreatic Ductal Adenocarcinoma
Letrozole
Low-Grade Serous Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
avutometinib | Phase 3 | Low Grade Serous Ovarian Cancer | - | - |
avutometinib (VS-6766) | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | - | - |
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | Phase 2 | KRAS Activating Mutation | - | - |
Avutometinib (VS-6766) + Defactinib (VS-6063) | Phase 2 | Low Grade Serous Ovarian Cancer | - | - |
defactinib (VS-6063) | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) and adagrasib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib and sotorasib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) and Defactinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
panitumumab | Phase 2 | Colorectal Cancer | - | - |
Duvelisib | Phase 2 | COVID-19 | - | - |
VS-6766 | Phase 2 | Breast Cancer | - | - |
Avutometinib (VS-6766) + defactinib | Phase 2 | Endometrioid Cancer | - | - |
Defactinib | Phase 2 | Pancreatic Adenocarcinoma | - | - |
Encorafenib | Phase 2 | Cutaneous Melanoma | - | - |
VS-7375 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Letrozole | Phase 2 | Low-Grade Serous Ovarian Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Verastem, Inc.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in Verastem, Inc.'s (VSTM) pipeline across Phase 3, Phase 2. Its lead program is avutometinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Verastem, Inc.'s next FDA catalyst?→
Verastem, Inc.'s (VSTM) next tracked catalyst is a Phase 2 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VSTM biotech catalysts?→
Add VSTM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Verastem, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.